Cryo Cell International INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
AMEX
Cryo-Cell International has received approval from the NYSE American for a compliance plan to address listing deficiencies, extending its deadline to September 9, 2027.
AMEX
Cryo-Cell International received a notice from NYSE American indicating non-compliance with continued listing standards due to a stockholders deficit and recent net losses.
AMEX
Cryo-Cell International, Inc. announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025, citing future decisions will depend on financial performance and strategic priorities.
AMEX
Cryo-Cell International amended its credit agreement with Susser Bank, extending maturity dates for its revolving credit and term loans while adjusting credit limits and interest margins.
AMEX
Cryo-Cell International, Inc. announced the dates for its 2025 Annual Meeting of Stockholders, including the meeting date, record date, and deadlines for stockholder proposals.
AMEX
Cryo-Cell International received a termination notice from Duke University for their Patent and Technology License Agreement, citing a breach of contract.
AMEX
Cryo-Cell International announces a reduced quarterly cash dividend of $0.15 per share due to the current economic environment and other capital allocation alternatives.
AMEX
Cryo-Cell International held its annual meeting on October 29, 2024, where stockholders elected four directors, ratified the company's independent auditor, and approved an advisory resolution on executive compensation.
AMEX
Cryo-Cell International announces the initiation of a regular quarterly cash dividend of $0.25 per share, marking a significant step in delivering value to shareholders.
AMEX
8-K: Cryo-Cell International Reports Fiscal Third Quarter 2024 Results, Revenue and Net Income Increase
Cryo-Cell International announced its fiscal third quarter 2024 results, showing an increase in both revenue and net income compared to the same period last year.
AMEX
Cryo-Cell International has announced the date for its 2024 Annual Meeting of Stockholders and the associated record date.
AMEX
Cryo-Cell International plans to spin off its subsidiary, Celle Corp., to shareholders and explore strategic options for the remaining company.